RESUMEN
Carotegrast-methyl (brand name: CAROGRA® Tablets) is a new chemical entity created by Ajinomoto Pharmaceuticals Co., Ltd. (currently EA Pharma Co., Ltd.) as an α4 integrin inhibitor. In vivo, it exerts an anti-inflammatory effect by inhibiting the functions of both α4ß1 integrin and α4ß7 integrin expressed on the surface of inflammatory cells such as lymphocytes. Under the joint development of EA Pharma Co., Ltd. and Kissei Pharmaceutical Co., Ltd., the efficacy and safety of carotegrast methyl were confirmed in patients with moderate active ulcerative colitis. Carotegrast-methyl, the Japan-originated, world-first orally available α4 integrin antagonist, was approved in March and launched in May 2022 in Japan. Patients who had inadequate response or intolerance to the basic treatment with 5-ASA preparations for ulcerative colitis, have widely desired an orally available treatment with the new mechanism of actions. Carotegrast methyl can be a treatment option that meets that unmet medical need and has the potential to greatly contribute to the treatment of ulcerative colitis based on the thorough practice of proper use. This article mainly introduces the pharmacological properties and clinical trial results of carotegrast methyl.
Asunto(s)
Colitis Ulcerosa , Humanos , Integrina alfa4 , Quinazolinonas , IntegrinasRESUMEN
We have experienced three gastric cancer cases successfully treated by the combination therapy of CDDP and TS-1. Case 1: 65-year-old man, a type 4 gastric cancer with huge abdominal para-aortic lymphnodes. Case 2: 74-year-old woman, a type 3 gastric cancer was found with obstructive jaundice. Swelling lymph nodes were seen in the hepatoduodenal ligament. Case 3: 58-year-old woman, a type 4 gastric cancer was found. The tumor invading the pancreas and swelling lymphnodes around the stomach were confirmed according to abdominal CT. Although combined chemotherapy of TS-1 plus CDDP is effective for advanced gastric cancer,adjuvant-chemotherapy must be investigated in noneffective cases.
